Metformin Affects Olaparib Sensitivity through Induction of Apoptosis in Epithelial Ovarian Cancer Cell Lines

被引:20
作者
Gralewska, Patrycja [1 ]
Gajek, Arkadiusz [1 ]
Marczak, Agnieszka [1 ]
Rogalska, Aneta [1 ]
机构
[1] Univ Lodz, Inst Biophys, Fac Biol & Environm Protect, Dept Med Biophys, PL-90236 Lodz, Poland
关键词
combination therapy; metformin; olaparib; ovarian cancer; PARP inhibitor; replication stress; BREAST-CANCER; MAINTENANCE THERAPY; PARP INHIBITORS; DOUBLE-BLIND; DNA-DAMAGE; IN-VITRO; P53; INCREASES; PATHWAY; PHENFORMIN;
D O I
10.3390/ijms221910557
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This study examined the effect of combination treatment with the poly (ADP-ribose) polymerase inhibitor olaparib and metformin on homologous recombination (HR)-proficient epithelial ovarian cancer (EOC). Ovarian cancer cell lines (OV-90 and SKOV-3) were treated with olaparib, metformin, or a combination of both. Cell viability was assessed by MTT and colony formation assays. The production of reactive oxygen species (ROS) and changes in mitochondrial membrane potential were examined using the specific fluorescence probes, DCFH2-DA (2 & PRIME;,7 & PRIME;-dichloro-dihydrofluorescein diacetate) and JC-1 (5,5 & PRIME;,6,6 & PRIME;-tetrachloro-1,1 & PRIME;,3,3 & PRIME;-tetraethylbenzimidazolcarbocyanine). Apoptotic and necrotic changes were measured by double staining with Hoechst 33258 and propidium iodide, orange acridine and ethidium bromide staining, phosphatidylserine externalization, TUNEL assay, caspase 3/7 activity, and cytochrome c and p53 expression. Compared with single-drug treatment, the combination of olaparib and metformin significantly inhibited cell proliferation and colony formation in HR-proficient ovarian cancer cells. ROS production preceded a decrease in mitochondrial membrane potential. The changes in ROS levels suggested their involvement in inducing apoptosis in response to combination treatment. The present results indicate a shift towards synergism in cells with mutant or null p53, treated with olaparib combined with metformin, providing a new approach to the treatment of gynecologic cancers. Taken together, the results support the use of metformin to sensitize EOC to olaparib therapy.
引用
收藏
页数:21
相关论文
共 95 条
[1]   Plakoglobin Reduces the in vitro Growth, Migration and Invasion of Ovarian Cancer Cells Expressing N-Cadherin and Mutant p53 [J].
Alaee, Mahsa ;
Danesh, Ghazal ;
Pasdar, Manijeh .
PLOS ONE, 2016, 11 (05)
[2]   Metformin treatment response is dependent on glucose growth conditions and metabolic phenotype in colorectal cancer cells [J].
Alhourani, Abdelnour H. ;
Tidwell, Tia R. ;
Bokil, Ansooya A. ;
Rosland, Gro, V ;
Tronstad, Karl Johan ;
Soreide, Kjetil ;
Hagland, Hanne R. .
SCIENTIFIC REPORTS, 2021, 11 (01)
[3]   Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test? [J].
Angeli, Davide ;
Salvi, Samanta ;
Tedaldi, Gianluca .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (03)
[4]   PARP-1 Inhibition Increases Mitochondrial Metabolism through SIRT1 Activation [J].
Bai, Peter ;
Canto, Caries ;
Oudart, Hugues ;
Brunyanszki, Attila ;
Cen, Yana ;
Thomas, Charles ;
Yamamoto, Hiroyasu ;
Huber, Aline ;
Kiss, Borbala ;
Houtkooper, Riekelt H. ;
Schoonjans, Kristina ;
Schreiber, Valerie ;
Sauve, Anthony A. ;
Menissier-de Murcia, Josiane ;
Auwerx, Johan .
CELL METABOLISM, 2011, 13 (04) :461-468
[5]   Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1 [J].
Baloch, Tahira ;
Lopez-Ozuna, Vanessa M. ;
Wang, Qiong ;
Matanis, Emad ;
Kessous, Roy ;
Kogan, Liron ;
Yasmeen, Amber ;
Gotlieb, Walter H. .
BMC CANCER, 2019, 19 (1)
[6]   Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes [J].
Beaufort, Corine M. ;
Helmijr, Jean C. A. ;
Piskorz, Anna M. ;
Hoogstraat, Marlous ;
Ruigrok-Ritstier, Kirsten ;
Besselink, Nicolle ;
Murtaza, Muhammed ;
van IJcken, Wilfred F. J. ;
Heine, Anouk A. J. ;
Smid, Marcel ;
Koudijs, Marco J. ;
Brenton, James D. ;
Berns, Els M. J. J. ;
Helleman, Jozien .
PLOS ONE, 2014, 9 (09)
[7]   Integrated genomic analyses of ovarian carcinoma [J].
Bell, D. ;
Berchuck, A. ;
Birrer, M. ;
Chien, J. ;
Cramer, D. W. ;
Dao, F. ;
Dhir, R. ;
DiSaia, P. ;
Gabra, H. ;
Glenn, P. ;
Godwin, A. K. ;
Gross, J. ;
Hartmann, L. ;
Huang, M. ;
Huntsman, D. G. ;
Iacocca, M. ;
Imielinski, M. ;
Kalloger, S. ;
Karlan, B. Y. ;
Levine, D. A. ;
Mills, G. B. ;
Morrison, C. ;
Mutch, D. ;
Olvera, N. ;
Orsulic, S. ;
Park, K. ;
Petrelli, N. ;
Rabeno, B. ;
Rader, J. S. ;
Sikic, B. I. ;
Smith-McCune, K. ;
Sood, A. K. ;
Bowtell, D. ;
Penny, R. ;
Testa, J. R. ;
Chang, K. ;
Dinh, H. H. ;
Drummond, J. A. ;
Fowler, G. ;
Gunaratne, P. ;
Hawes, A. C. ;
Kovar, C. L. ;
Lewis, L. R. ;
Morgan, M. B. ;
Newsham, I. F. ;
Santibanez, J. ;
Reid, J. G. ;
Trevino, L. R. ;
Wu, Y. -Q. ;
Wang, M. .
NATURE, 2011, 474 (7353) :609-615
[8]   Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery [J].
Budiana, I. Nyoman Gede ;
Angelina, Michelle ;
Pemayun, Tjokorda Gede Astawa .
JOURNAL OF THE TURKISH-GERMAN GYNECOLOGICAL ASSOCIATION, 2019, 20 (01) :47-54
[9]   Clinical Value of lncRNA MEG3 in High-Grade Serous Ovarian Cancer [J].
Buttarelli, Marianna ;
De Donato, Marta ;
Raspaglio, Giuseppina ;
Babini, Gabriele ;
Ciucci, Alessandra ;
Martinelli, Enrica ;
Baccaro, Pina ;
Pasciuto, Tina ;
Fagotti, Anna ;
Scambia, Giovanni ;
Gallo, Daniela .
CANCERS, 2020, 12 (04)
[10]  
Cantor SB, 2011, FUTURE ONCOL, V7, P253, DOI [10.2217/fon.10.191, 10.2217/FON.10.191]